Restoration of Noradrenergic Function in Parkinson's Disease Model Mice

被引:10
|
作者
Cui, Kui [1 ]
Yang, Fan [1 ,2 ]
Tufan, Turan [1 ]
Raza, Muhammad U. [1 ]
Zhan, Yanqiang [1 ,3 ]
Fan, Yan [1 ,4 ]
Zeng, Fei [1 ,3 ]
Brown, Russell W. [1 ]
Price, Jennifer B. [5 ]
Jones, Thomas C. [5 ]
Miller, Gary W. [6 ]
Zhu, Meng-Yang [1 ,7 ]
机构
[1] East Tennessee State Univ, Quillen Coll Med, Dept Biomed Sci, Johnson City, TN 37604 USA
[2] Asia Metropolitan Univ, Hong Kong Inst, Hong Kong, Peoples R China
[3] Wuhan Univ, Dept Neurol, Renmin Hosp, Wuhan, Peoples R China
[4] Nantong Univ, Dept Biochem, Coll Med, Nantong, Peoples R China
[5] East Tennessee State Univ, Dept Biol Sci, Coll Arts & Sci, Johnson City, TN 37604 USA
[6] Columbia Univ, Mailmen Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA
[7] Harvard Med Sch, Karp Family Res Labs, Dept Surg, Boston Childrens Hosp, Boston, MA 02115 USA
来源
ASN NEURO | 2021年 / 13卷
关键词
locus coeruleus; norepinephrine; tyrosine hydroxylase; dopamine; dopamine β -hydroxylase; Morris water maze; DOPAMINE-BETA-HYDROXYLASE; NEUROTROPHIC FACTOR EXPRESSION; REDUCED VESICULAR STORAGE; MORRIS WATER MAZE; NIGRAL CELL LOSS; LOCUS-COERULEUS; TRANSCRIPTION FACTOR; NOREPINEPHRINE TRANSPORTER; GENE-THERAPY; MOUSE MODEL;
D O I
10.1177/17590914211009730
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Dysfunction of the central noradrenergic and dopaminergic systems is the primary neurobiological characteristic of Parkinson's disease (PD). Importantly, neuronal loss in the locus coeruleus (LC) that occurs in early stages of PD may accelerate progressive loss of dopaminergic neurons. Therefore, restoring the activity and function of the deficient noradrenergic system may be an important therapeutic strategy for early PD. In the present study, the lentiviral constructions of transcription factors Phox2a/2b, Hand2 and Gata3, either alone or in combination, were microinjected into the LC region of the PD model VMAT2 Lo mice at 12 and 18 month age. Biochemical analysis showed that microinjection of lentiviral expression cassettes into the LC significantly increased mRNA levels of Phox2a, and Phox2b, which were accompanied by parallel increases of mRNA and proteins of dopamine beta-hydroxylase (DBH) and tyrosine hydroxylase (TH) in the LC. Furthermore, there was considerable enhancement of DBH protein levels in the frontal cortex and hippocampus, as well as enhanced TH protein levels in the striatum and substantia nigra. Moreover, these manipulations profoundly increased norepinephrine and dopamine concentrations in the striatum, which was followed by a remarkable improvement of the spatial memory and locomotor behavior. These results reveal that over-expression of these transcription factors in the LC improves noradrenergic and dopaminergic activities and functions in this rodent model of PD. It provides the necessary groundwork for the development of gene therapies of PD, and expands our understanding of the link between the LC-norepinephrine and dopamine systems during the progression of PD.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Intranasal Stem Cells for Parkinson's Disease Model in Mice
    Sabry, Dina
    Salama, Mohamed
    Sobh, Mahmoud
    Emam, Mahmoud
    El-Gamal, Mohamed
    Abdalla, Ahmed
    Lotfy, Ahmed
    El-Qotb, Mahmoud
    Sobh, Mohamed
    NEUROLOGY, 2016, 86
  • [22] Enteric neuronal function and colonic motility in PINK1-/- mice: A model for Parkinson's Disease
    Vanden Berghe, P.
    Martin Cano, F. E.
    Dondeyne, M.
    Boesmans, W.
    Morais, V.
    De Strooper, B.
    Pozo, M. J.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2012, 24 : 49 - 49
  • [23] Restoration of locomotive function in Parkinson's disease by spinal cord stimulation: mechanistic approach
    Fuentes, Romulo
    Petersson, Per
    Nicolelis, Miguel A. L.
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2010, 32 (07) : 1100 - 1108
  • [24] Evaluation of gastrointestinal function in a mouse model of Parkinson's disease
    Anderson, G.
    Taylor, G.
    Bernhard, D.
    Anitha, M.
    Srinivasan, S.
    Greene, J. G.
    MOVEMENT DISORDERS, 2007, 22 : S18 - S18
  • [25] Sympathetic noradrenergic denervation in Parkinson disease
    Goldstein, DS
    Holmes, C
    Sharabi, Y
    HYPERTENSION, 2005, 46 (04) : 815 - 815
  • [26] Sympathetic noradrenergic denervation in Parkinson disease
    Goldstein, DS
    Eldadah, B
    Holmes, C
    Pechnik, S
    Moak, J
    Saleem, A
    Sharabi, Y
    FASEB JOURNAL, 2006, 20 (05): : A1418 - A1419
  • [27] Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease
    Cao, Lei-Fang
    Peng, Xiao-Yan
    Huang, Ya
    Wang, Bing
    Zhou, Feng-Ming
    Cheng, Ruo-Xiao
    Chen, Li-Hua
    Luo, Wei-Feng
    Liu, Tong
    NEURAL PLASTICITY, 2016, 2016
  • [28] Targeting the noradrenergic system for anti-inflammatory and neuroprotective actions in an animal model of Parkinson's disease
    Yssel, Justin D.
    Connor, Thomas
    Harkin, Andrew
    IRISH JOURNAL OF MEDICAL SCIENCE, 2016, 185 : S181 - S181
  • [29] Behavioural characterization of engrailed mutant mice as model of Parkinson's disease
    Pinna, A.
    Pontis, S.
    Sgado, P.
    Corsini, G. U.
    Morelli, M.
    BEHAVIOURAL PHARMACOLOGY, 2007, 18 : S38 - S38
  • [30] Rotenone model of Parkinson's disease: The dosing options in mice revisited
    Raza, M.
    Zehra, N.
    Malhi, S.
    MOVEMENT DISORDERS, 2018, 33 : S405 - S405